Amedisys Agrees to Divest Home Health Centers
Deal News | May 08, 2025 | TT Capital Partners LLC
In the latest issue of Healthcare M&A Weekly, significant movements within the industry showcase a dynamic wave of mergers, acquisitions, and partnerships focused on the intersection of healthcare technology and services. Key transactions include Amedisys's divestment agreements with affiliates of the Pennant Group and BrightSpring Health Services, and Archer Review's acquisition of PulsedIn's core technology. TidalHealth and Atlantic General Hospital are set for a merger under a definitive agreement, and ChiroHD has secured funding from Mainsail Partners to enhance its chiropractor practice management. Consumer Edge has completed its acquisition of Earnest Analytics, strengthening its position in healthcare data intelligence. Another notable acquisition is by ENT Partners who have added Currence Physician Solutions to their portfolio. EyeMD EMR received growth investment from Performant Capital, while Extendicare's ParaMed is acquiring Closing the Gap Healthcare Group. Healthy.io’s acquisition of Labrador Health and numerous other transactions signify robust strategic moves in the healthcare sector. Additionally, Madison Dearborn Partners and Thoma Bravo are set to gain a significant stake in NextGen Healthcare. Major pharmaceutical and biotech transactions include Merck's acquisition of SpringWorks for $3.9 billion, and Regulus Therapeutics' acquisition by Novartis for initial cash considerations of $800 million. Furthermore, Persivia has undergone a recapitalization with Aldrich Capital. These transactions underline critical trends and strategic alliances forming the future landscape of healthcare business operations.
Sectors
- Healthcare
- Private Equity
- Technology
Geography
- United States – Many of the companies involved in the M&A transactions such as Merck, Extendicare, and TidalHealth are based in or operate within the United States.
- Germany – Merck KGaA, a key participant in the M&A activities discussed, is a Germany-based company.
- Japan – Ajinomoto Co., involved in a transaction with PCI Pharma Services, is based in Japan.
Industry
- Healthcare – The article primarily discusses M&A activities in the healthcare sector, including hospitals, health technology firms, and biotech companies.
- Private Equity – The article references investments and ownership stakes by private equity firms in various healthcare companies, indicating the involvement of the private equity industry.
- Technology – Several transactions involve healthcare technology companies or firms that provide tech-enabled solutions, highlighting this as a critical industry in the article.
Financials
- $3.9B – Equity value of Merck KGaA's acquisition of SpringWorks Therapeutics.
- $800M – Initial cash payment for Novartis AG's acquisition of Regulus Therapeutics Inc.
- $26M – Growth capital secured by ChiroHD from Mainsail Partners.
- $107M – Recapitalization amount completed by Persivia with Aldrich Capital Partners.
- $30M – Cash transaction amount for which Teladoc Health acquired UpLift.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Amedisys | Target | Company | A healthcare company involved in divestment agreements in the home health and hospice care sectors. |
| Pennant Group | Buyer | Company | An affiliate involved in the acquisition of divested assets from Amedisys. |
| BrightSpring Health Services | Buyer | Company | An affiliate involved in the acquisition of divested assets from Amedisys. |
| Madison Dearborn Partners | Buyer | Company | A private equity investment firm acquiring significant ownership in NextGen Healthcare. |
| Thoma Bravo | Partner | Company | A software investment firm partnering with Madison Dearborn in acquiring NextGen Healthcare. |
| Merck KGaA | Buyer | Company | A Germany-based pharmaceutical company acquiring SpringWorks Therapeutics. |
| SpringWorks Therapeutics | Target | Company | A U.S. biotech company developing rare cancer therapies, acquired by Merck. |
| Novartis AG | Buyer | Company | A pharmaceutical company acquiring Regulus Therapeutics. |
| Regulus Therapeutics Inc. | Target | Company | A biopharmaceutical company focused on medicines targeting microRNAs, acquired by Novartis. |
| TT Capital Partners LLC | Source | Company | The private equity firm providing the M&A Weekly summary. |